A Virtual Intervention to Improve Medication Adherence in Pediatric Cancer: MedSupport
1 other identifier
interventional
16
1 country
1
Brief Summary
To develop a cancer center level practice intervention to promote treatment adherence and reduce outcome disparities in pediatric cancer survivors
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Apr 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 24, 2021
CompletedFirst Posted
Study publicly available on registry
December 8, 2021
CompletedStudy Start
First participant enrolled
April 11, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 6, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
June 6, 2024
CompletedSeptember 19, 2024
September 1, 2024
2 months
November 24, 2021
September 12, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Retention rates
Feasibility of intervention as assessed by retention rates
Up to 8 weeks
Secondary Outcomes (2)
Feasibility of universal SDOA screening
up to 8 weeks
Provider satisfaction with barrier reports
up to 8 weeks
Study Arms (2)
Intervention - Pediatric parent/caregiver
EXPERIMENTALQuestionnaires along with educational videos
Clinicians
EXPERIMENTALWill complete pre and post survey about medication education practices
Interventions
How many times a 7 question Survey on medication education practices is opened
Eligibility Criteria
You may qualify if:
- Parents/caregivers of pediatric patients must meet the following criteria to be eligible:
- Parents/guardians of child that has been diagnosed with any cancer.
- Parents/guardians of child with any cancer between age 0 and 18.
- Parents/guardians of child on home-based oral anti-cancer therapy or supportive care therapy.
- The clinician for the family agrees to participate in the study.
You may not qualify if:
- Participants will be excluded from this study if unwilling or unable to complete the assessment in English
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Elizabeth Bouchard, MD
Roswell Park Comprehensive Cancer Center
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 24, 2021
First Posted
December 8, 2021
Study Start
April 11, 2023
Primary Completion
June 6, 2023
Study Completion
June 6, 2024
Last Updated
September 19, 2024
Record last verified: 2024-09